单唾液酸神经节苷脂治疗急性脊髓损伤的效果研究(1)
【摘要】 目的 探討单唾液酸神经节苷脂治疗急性脊髓损伤的效果。方法 72例急性脊髓损伤患者为研究对象， 随机分成对照组与观察组， 每组36例。两组均予以甲基强的松龙、丙种球蛋白、雷尼替丁、维生素B等基础治疗， 观察组同时使用单唾液酸神经节苷脂。比较两组的运动、感觉功能评分;不良反应发生情况。结果 治疗前， 对照组运动、感觉功能评分分别为(21.6±3.1)、(17.9±2.4)分， 观察组运动、感觉功能评分分别为(21.5±3.2)、(18.2±2.5)分， 比较差异无统计学意义(P>0.05)。治疗后， 对照组运动、感觉功能评分分别为(26.2±3.2)、(22.3±2.3)分， 观察组运动、感觉功能评分分别为(32.6±3.3)、(26.5±2.4)分， 两组运动、感觉功能评分均明显高于治疗前， 且观察组运动、感觉功能评分均明显高于对照组， 差异有统计学意义(P<0.05)。观察组不良反应发生率为8.3%(3/36)， 对照组不良反应发生率为11.1%(4/36)， 比较差异无统计学意义(P>0.05)。两组治疗过程中均无严重不良反应， 不良反应症状均于停药后自行缓解。结论 单唾液酸神经节苷脂可促进急性脊髓损伤患者神经功能的恢复， 无明显不良反应， 安全性良好。
【关键词】 单唾液酸神经节苷脂;急性脊髓损伤;治疗效果
DOI：10.14163/j.cnki.11-5547/r.2019.16.003
Study on effect of monosialoganglioside on the ttreatment of acute spinal cord injury DONG Zhi-yong. Department of Orthopaedics， Shandong Heze Caoxian County Hospital， Heze 274400， China
【Abstract】 Objective To discuss the effect of monosialoganglioside on the ttreatment of acute spinal cord injury. Methods A total of 72 patients with acute spinal cord injury as study subjects were randomly divided into control group and observation group， with 36 cases in each group. Both groups were treated with methylprednisolone， gamma globulin， ranitidine and vitamin B， and the observation group was also treated with monosialoganglioside at the same time. Comparison were made on motor and sensory function scores and occurrence of adverse reactions between the two groups. Results Before treatment， the control group had motor and sensory function scores respectively as (21.6±3.1) and (17.9±2.4) points， which were (21.5±3.2) and (18.2±2.5) points in the observation group. Their difference was not statistically significant (P>0.05). After treatment， the control group had motor and sensory function scores respectively as (26.2±3.2) and (22.3±
2.3) points， which were (32.6±3.3) and (26.5±2.4) points in the observation group. Both groups had obviously higher motor and sensory function scores than those before treatment， and the observation group had obviously higher motor and sensory function scores than the control group. Their difference was statistically significant (P<0.05). The observation group had incidence of adverse reactions as 8.3%(3/36)， which was 11.1%(4/36) in the control group， and the difference was not statistically significant (P>0.05). There were no serious adverse reactions in both groups during the course of treatment. The symptoms of adverse reactions could be alleviated by themselves after discontinuation of drugs. Conclusion Monosialoganglioside can promote the recovery of neurological function in patients with acute spinal cord injury with no obvious adverse reactions and high safety., http://www.100md.com(董志勇)
【关键词】 单唾液酸神经节苷脂;急性脊髓损伤;治疗效果
DOI：10.14163/j.cnki.11-5547/r.2019.16.003
Study on effect of monosialoganglioside on the ttreatment of acute spinal cord injury DONG Zhi-yong. Department of Orthopaedics， Shandong Heze Caoxian County Hospital， Heze 274400， China
【Abstract】 Objective To discuss the effect of monosialoganglioside on the ttreatment of acute spinal cord injury. Methods A total of 72 patients with acute spinal cord injury as study subjects were randomly divided into control group and observation group， with 36 cases in each group. Both groups were treated with methylprednisolone， gamma globulin， ranitidine and vitamin B， and the observation group was also treated with monosialoganglioside at the same time. Comparison were made on motor and sensory function scores and occurrence of adverse reactions between the two groups. Results Before treatment， the control group had motor and sensory function scores respectively as (21.6±3.1) and (17.9±2.4) points， which were (21.5±3.2) and (18.2±2.5) points in the observation group. Their difference was not statistically significant (P>0.05). After treatment， the control group had motor and sensory function scores respectively as (26.2±3.2) and (22.3±
2.3) points， which were (32.6±3.3) and (26.5±2.4) points in the observation group. Both groups had obviously higher motor and sensory function scores than those before treatment， and the observation group had obviously higher motor and sensory function scores than the control group. Their difference was statistically significant (P<0.05). The observation group had incidence of adverse reactions as 8.3%(3/36)， which was 11.1%(4/36) in the control group， and the difference was not statistically significant (P>0.05). There were no serious adverse reactions in both groups during the course of treatment. The symptoms of adverse reactions could be alleviated by themselves after discontinuation of drugs. Conclusion Monosialoganglioside can promote the recovery of neurological function in patients with acute spinal cord injury with no obvious adverse reactions and high safety., http://www.100md.com(董志勇)